Free Trial

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BlueRiver Acquisition Corp. stock logo
BLUA
BlueRiver Acquisition
$11.02
-0.3%
$10.93
$10.24
$11.45
$96.21MN/A31,504 shs500 shs
Neovasc Inc. stock logo
NVCN
Neovasc
$30.03
$29.69
$4.59
$30.07
$82.28M1.756,993 shs1 shs
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
$5.00
+0.2%
$5.27
$2.51
$6.97
$66.65M1.1103,048 shs52,612 shs
Neuronetics, Inc. stock logo
STIM
Neuronetics
$2.53
-3.1%
$3.82
$1.03
$5.07
$75.90M2.5181,818 shs69,823 shs
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BlueRiver Acquisition Corp. stock logo
BLUA
BlueRiver Acquisition
0.00%0.00%+0.36%+2.89%+7.41%
Neovasc Inc. stock logo
NVCN
Neovasc
0.00%0.00%0.00%0.00%0.00%
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
0.00%-0.20%+8.01%-0.60%+30.63%
Neuronetics, Inc. stock logo
STIM
Neuronetics
0.00%+3.98%-31.32%-15.81%-3.69%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BlueRiver Acquisition Corp. stock logo
BLUA
BlueRiver Acquisition
N/AN/AN/AN/AN/AN/AN/AN/A
Neovasc Inc. stock logo
NVCN
Neovasc
N/AN/AN/AN/AN/AN/AN/AN/A
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
0.019 of 5 stars
0.01.00.00.00.01.70.6
Neuronetics, Inc. stock logo
STIM
Neuronetics
2.4295 of 5 stars
3.53.00.00.02.51.70.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BlueRiver Acquisition Corp. stock logo
BLUA
BlueRiver Acquisition
N/AN/AN/AN/A
Neovasc Inc. stock logo
NVCN
Neovasc
N/AN/AN/AN/A
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
N/AN/AN/AN/A
Neuronetics, Inc. stock logo
STIM
Neuronetics
3.00
Buy$8.00216.21% Upside

Current Analyst Ratings

Latest NVCN, STIM, BLUA, and NVNO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/14/2024
Neuronetics, Inc. stock logo
STIM
Neuronetics
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform
3/26/2024
Neuronetics, Inc. stock logo
STIM
Neuronetics
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform
3/6/2024
Neuronetics, Inc. stock logo
STIM
Neuronetics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$7.00 ➝ $8.00
(Data available from 5/20/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BlueRiver Acquisition Corp. stock logo
BLUA
BlueRiver Acquisition
N/AN/AN/AN/A($0.72) per shareN/A
Neovasc Inc. stock logo
NVCN
Neovasc
$3.81M21.60N/AN/A$5.77 per share5.20
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
N/AN/AN/AN/A$3.47 per shareN/A
Neuronetics, Inc. stock logo
STIM
Neuronetics
$71.35M1.06N/AN/A$1.18 per share2.14

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BlueRiver Acquisition Corp. stock logo
BLUA
BlueRiver Acquisition
-$5.28MN/A0.00N/AN/AN/A-34.53%N/A
Neovasc Inc. stock logo
NVCN
Neovasc
-$41.20M-$15.08N/AN/A-1,082.92%-127.25%-80.31%N/A
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
-$23.52M-$1.66N/AN/AN/AN/A-62.17%-57.58%7/29/2024 (Estimated)
Neuronetics, Inc. stock logo
STIM
Neuronetics
-$30.19M-$0.96N/AN/AN/A-37.61%-75.84%-26.67%8/13/2024 (Estimated)

Latest NVCN, STIM, BLUA, and NVNO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2024Q1 2024
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
N/A-$0.31-$0.31-$0.31N/AN/A
3/5/202412/31/2023
Neuronetics, Inc. stock logo
STIM
Neuronetics
-$0.26-$0.19+$0.07-$0.19$19.73 million$20.31 million    
2/29/2024Q4 2023
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
N/A-$0.32-$0.32-$0.32N/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BlueRiver Acquisition Corp. stock logo
BLUA
BlueRiver Acquisition
N/AN/AN/AN/AN/A
Neovasc Inc. stock logo
NVCN
Neovasc
N/AN/AN/AN/AN/A
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
N/AN/AN/AN/AN/A
Neuronetics, Inc. stock logo
STIM
Neuronetics
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BlueRiver Acquisition Corp. stock logo
BLUA
BlueRiver Acquisition
N/A
0.01
0.01
Neovasc Inc. stock logo
NVCN
Neovasc
0.80
2.96
2.85
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
N/A
29.08
29.08
Neuronetics, Inc. stock logo
STIM
Neuronetics
2.15
5.65
5.18

Ownership

Institutional Ownership

CompanyInstitutional Ownership
BlueRiver Acquisition Corp. stock logo
BLUA
BlueRiver Acquisition
22.34%
Neovasc Inc. stock logo
NVCN
Neovasc
1.64%
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
34.71%
Neuronetics, Inc. stock logo
STIM
Neuronetics
53.59%

Insider Ownership

CompanyInsider Ownership
BlueRiver Acquisition Corp. stock logo
BLUA
BlueRiver Acquisition
78.98%
Neovasc Inc. stock logo
NVCN
Neovasc
N/A
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
17.00%
Neuronetics, Inc. stock logo
STIM
Neuronetics
9.80%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
BlueRiver Acquisition Corp. stock logo
BLUA
BlueRiver Acquisition
38.73 million1.84 millionNot Optionable
Neovasc Inc. stock logo
NVCN
Neovasc
492.74 millionN/ANot Optionable
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
1913.33 million11.06 millionOptionable
Neuronetics, Inc. stock logo
STIM
Neuronetics
20330.00 million27.06 millionOptionable

NVCN, STIM, BLUA, and NVNO Headlines

Recent News About These Companies

Neuronetics: Reality Set In
Neuronetics Inc.

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

BlueRiver Acquisition logo

BlueRiver Acquisition

NYSE:BLUA
BlueRiver Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It intends to identify business opportunities in the field of technology, media, telecom, and entertainment industries. The company was incorporated in 2020 and is based in San Antonio, Texas.
Neovasc logo

Neovasc

NASDAQ:NVCN
Neovasc, Inc. engages in the development, manufacture and marketing of medical devices. It focuses on Neovast Tiara and Neovasc Reducer products. The company was founded on November 2, 2000 and is headquartered in Richmond, Canada.
enVVeno Medical logo

enVVeno Medical

NASDAQ:NVNO
enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company's lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI). Deep venous CVI occurs when valves inside of the deep veins of the leg become damaged, resulting in insufficient blood being returned to the heart. The malfunctioning vein valves cause blood to flow backwards (reflux) and pool in the lower leg, increasing the pressure within the veins of the leg (venous hypertension). In the most severe cases, CVI can lead to venous ulcers (open skin sores) that become chronic and difficult to heal. The VenoValve is implanted in the femoral vein and works as a replacement venous valve, designed to reduce reflux and venous hypertension, and to restore proper directional blood flow back to the heart. With severe deep venous CVI impacting an estimated 2.4 million people in the U.S., who have no effective treatment options, the VenoValve has received Breakthrough Device Designation from the U.S. Food and Drug Administration, and is currently being evaluated in the SAVVE U.S. clinical trial.
Neuronetics logo

Neuronetics

NASDAQ:STIM
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.